These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 28986550)
41. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306 [TBL] [Abstract][Full Text] [Related]
42. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246 [TBL] [Abstract][Full Text] [Related]
43. The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Zhang K; Chow PK Clin Cancer Res; 2004 Aug; 10(15):5226-32. PubMed ID: 15297426 [TBL] [Abstract][Full Text] [Related]
44. Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells. Wakimoto R; Ono M; Takeshima M; Higuchi T; Nakano S Anticancer Res; 2017 Nov; 37(11):6153-6159. PubMed ID: 29061796 [TBL] [Abstract][Full Text] [Related]
45. A rare event of megestrol acetate (Megace)-induced adrenal suppression in a breast cancer patient. Fried G; Stein M; Haim N Am J Clin Oncol; 1997 Dec; 20(6):628-9. PubMed ID: 9391555 [No Abstract] [Full Text] [Related]
46. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice]. Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587 [TBL] [Abstract][Full Text] [Related]
47. [Therapy of advanced endometrial cancer]. Okada H; Yamamoto T Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105 [TBL] [Abstract][Full Text] [Related]
48. Uterine adenocarcinoma metastatic to the skin responsive to megestrol acetate. Spencer DM; Bigler LR; Wilkin JK; Gams RA J Dermatol Surg Oncol; 1994 Aug; 20(8):544-7. PubMed ID: 8056889 [TBL] [Abstract][Full Text] [Related]
49. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Leiser AL; Hamid AM; Blanchard R Gynecol Oncol; 2004 Aug; 94(2):567-71. PubMed ID: 15297205 [TBL] [Abstract][Full Text] [Related]
50. The antiproliferative effects of pterostilbene on breast cancer in vitro are via inhibition of constitutive and leptin-induced Janus kinase/signal transducer and activator of transcription activation. McCormack D; Schneider J; McDonald D; McFadden D Am J Surg; 2011 Nov; 202(5):541-4. PubMed ID: 21944294 [TBL] [Abstract][Full Text] [Related]
51. Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate. Shirali E; Yarandi F; Eftekhar Z; Shojaei H; Khazaeipour Z Arch Gynecol Obstet; 2012 Mar; 285(3):791-5. PubMed ID: 21805142 [TBL] [Abstract][Full Text] [Related]
52. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer. Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263 [TBL] [Abstract][Full Text] [Related]
53. Amorfrutin A inhibits TNF-α induced JAK/STAT signaling, cell survival and proliferation of human cancer cells. Mi C; Ma J; Wang KS; Wang Z; Li MY; Li JB; Li X; Piao LX; Xu GH; Jin X Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):338-347. PubMed ID: 28879797 [TBL] [Abstract][Full Text] [Related]
55. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression. Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897 [TBL] [Abstract][Full Text] [Related]
56. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883 [TBL] [Abstract][Full Text] [Related]
57. Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. Oliveras-Ferraros C; Fernández-Arroyo S; Vazquez-Martin A; Lozano-Sánchez J; Cufí S; Joven J; Micol V; Fernández-Gutiérrez A; Segura-Carretero A; Menendez JA Int J Oncol; 2011 Jun; 38(6):1533-47. PubMed ID: 21455577 [TBL] [Abstract][Full Text] [Related]
58. Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial. Moradan S; Nikkhah N; Mirmohammadkhanai M Adv Ther; 2017 May; 34(5):1211-1220. PubMed ID: 28353144 [TBL] [Abstract][Full Text] [Related]
59. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. Rowland KM; Loprinzi CL; Shaw EG; Maksymiuk AW; Kuross SA; Jung SH; Kugler JW; Tschetter LK; Ghosh C; Schaefer PL; Owen D; Washburn JH; Webb TA; Mailliard JA; Jett JR J Clin Oncol; 1996 Jan; 14(1):135-41. PubMed ID: 8558188 [TBL] [Abstract][Full Text] [Related]
60. Fertility-sparing therapy for young women with endometrial cancer. Frumovitz M; Gershenson DM Expert Rev Anticancer Ther; 2006 Jan; 6(1):27-32. PubMed ID: 16375641 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]